Servicio de Endocrinología y Nutrición, Hospital Universitario Clínico San Carlos, Madrid, España.
Servicio de Radiodiagnóstico, Hospital Universitario Clínico San Carlos, Madrid, España.
Endocrinol Diabetes Nutr (Engl Ed). 2020 Mar;67(3):164-171. doi: 10.1016/j.endinu.2019.06.003. Epub 2019 Aug 19.
To evaluate the efficacy and safety of one single-session of radiofrequency ablation (RFA) performed in thyroid benign and predominantly solid nodules.
Unicentric retrospective study in usual clinical setting that included patients with solid and benign thyroid nodules treated with one single session of RFA and with folllow-up of at at least 6 months after the procedure. RFA was performed as an alternative to surgery in cases of pressure symptoms or nodular growth evidence. Patients were evaluated basally and at one, 3 and 6 months after RFA and also at 12 months if the follow-up was available. In each evaluation efficacy variables were recorded (percentual change from basal volume, percentage of nodules reaching a volume reduction above 50% from baseline, patients with disappearance of pressure symptoms and the possibility of antithyroid drug withdrawal) and safety variables were also registered including minor complications (pain needing analgesic drugs, hematoma) and major complications (voice changes, braquial plexus injury, nodule rupture and thyroid dysfunction).
Twenty-four patients with a follow-up of at least 6 months after RFA were included, 16 of them with more than 12 months of follow-up. Mean nodule volume changed from 25.4±15.5ml basally to 10.7±9.9ml at month 6 (P<.05) and to 9.9±10,4ml at month 12 in 16 nodules. Six months after RFA mean volumetric reduction was 57.5±24% and 65% of the nodules reached a volume reduction above 50% from baseline. Median percentage of reduction at month 6 was 50.4±25.8% for nodules with a basal volume above 20ml (n=13) and 65.3±20.1% for nodules with a lower basal volume (n=11). Pressure symptoms reported in 12 patients disappeared in all cases. Antithyroid drugs could be stopped in 3 of 4 cases treated before RFA. A mild and transient pain responsive to conventional analgesic drugs was recorded in 9 patients during the 24h after the procedure and in 7 a small perithyroid and transient hematoma was observed in the 48 following hours. One major complication was described as a nodule rupture that recovered spontaneously. There were no changes in hormonal values in euthyroid cases.
A single session of RFA seems to be an effective and safe procedure in patients with solid thyroid nodules with pressure symptoms or relevant growth evidence. As an outpatient and scarless procedure with no need of general anaesthesia it could become an useful alternative to lobectomy when surgery is refused or in patients at high surgical risk.
评估单次射频消融(RFA)治疗甲状腺良性和主要实性结节的疗效和安全性。
在常规临床环境中进行的单中心回顾性研究,纳入了接受单次 RFA 治疗且在术后至少 6 个月进行随访的实性和良性甲状腺结节患者。对于有压迫症状或结节生长证据的患者,RFA 被作为手术的替代方法。在 RFA 后 1、3 和 6 个月以及如果有随访的话在 12 个月时对患者进行基础和随访评估。在每次评估中,记录疗效变量(从基础体积的百分比变化、达到基线体积减少 50%以上的结节百分比、压迫症状消失的患者和停用抗甲状腺药物的可能性)和安全性变量,包括轻微并发症(需要止痛药的疼痛、血肿)和主要并发症(声音改变、臂丛神经损伤、结节破裂和甲状腺功能障碍)。
纳入了 24 例至少随访 6 个月的 RFA 患者,其中 16 例随访时间超过 12 个月。16 个结节的平均结节体积从基础时的 25.4±15.5ml 降至 6 个月时的 10.7±9.9ml(P<.05)和 12 个月时的 9.9±10.4ml。6 个月时的平均体积减少率为 57.5±24%,65%的结节体积减少了基线体积的 50%以上。对于基础体积大于 20ml(n=13)的结节,6 个月时的中位体积减少率为 50.4±25.8%,对于基础体积较小(n=11)的结节,体积减少率为 65.3±20.1%。12 例报告有压迫症状的患者均完全缓解。在 RFA 治疗前,4 例中有 3 例可以停用抗甲状腺药物。9 例患者在术后 24 小时内记录到轻度和短暂的疼痛,对常规止痛药有反应,7 例患者在接下来的 48 小时内观察到甲状腺周围小的、短暂的血肿。描述了 1 例主要并发症为结节破裂,自发恢复。甲状腺功能正常的患者激素值无变化。
对于有压迫症状或有明显生长证据的实性甲状腺结节患者,单次 RFA 似乎是一种有效且安全的治疗方法。作为一种门诊和无痕手术,无需全身麻醉,当手术被拒绝或患者有较高的手术风险时,它可以成为甲状腺叶切除术的有用替代方法。